¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high cellular component"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cellular cast
    ¼¼Æ÷¿øÁÖ
  • cellular cementum
    ¼¼Æ÷½Ã¸àÆ®Áú
  • cellular immunity
    ¼¼Æ÷¸é¿ª
  • cellular infiltration
    ¼¼Æ÷ħÀ±
  • cellular invagination
    ¼¼Æ÷ÇÔÀÔ
  • cellular ischemia
    ¼¼Æ÷ÇãÇ÷
  • cellular migration
    ¼¼Æ÷À̵¿
  • cellular nevus
    ¼¼Æ÷Ãæ½Ç¸ð¹Ý
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • cellular protooncogene
    ¼¼Æ÷DzÁ¾¾çÀ¯ÀüÀÚ
  • cellular radiobiology
    ¼¼Æ÷¹æ»ç¼±»ý¹°ÇÐ
  • cellular sensitivity
    ¼¼Æ÷¹Î°¨µµ
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • high altitude
    °íÁö-, °í¼Ò-
  • high altitude illness
    °í¼Òº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cellular antibody
    ¼¼Æ÷Ç×ü
  • cellular
    ¼¼Æ÷-
  • cellular cartilage
    ¼¼Æ÷¿¬°ñ
  • cellular cast
    ¼¼Æ÷¿ø±âµÕ, ¼¼Æ÷¿øÁÖ
  • cellular cementum
    ¼¼Æ÷½Ã¸àÆ®Áú
  • cellular immunity
    (¢¡cell-mediated immunity) ¼¼Æ÷¸Å°³¸é¿ª
  • cellular infiltration
    ¼¼Æ÷ħÀ±
  • cellular invagination
    ¼¼Æ÷ÇÔÀÔ
  • cellular ischemia
    ±¹¼ÒÇãÇ÷
  • cellular migration
    ¼¼Æ÷À̵¿
  • cellular nevus
    ¼¼Æ÷¸ð¹Ý
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • cellular protooncogene
    ¼¼Æ÷¿ø¹ß¾ÏÀ¯ÀüÀÚ
  • cellular radiobiology
    ¼¼Æ÷¹æ»ç¼±»ý¹°ÇÐ
  • cellular sensitivity
    ¼¼Æ÷¹Î°¨µµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
  • high dizziness
    °í¼ÒÇö±âÁõ(Ë­ËÛ̴˻̡).
  • high dose rate
    °í¼±·®À²
  • high dose rate intraluminal radiotherapy
    °í¼±·®À² °ü³»¹æ»ç¼±Ä¡·á
  • high dose tolerance
    °ú·®°ü¿ë
  • high echo area
    °í ¿¡ÄÚ ±¸¿ª
  • high echo area
    °í (ÍÔ) ¿¡ÄÚ ¿ª (æ´)
  • high electron density
    °íÀüÀڹеµ(ÍÔï³í­ÚËöô).
  • high energy bond
    °í¿¡³ÊÁö °áÇÕ
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ.
  • high energy phosphate bond
    °í¿¡³ÊÁöÀλ꿰°áÇÕ.
  • high energy radiation
    °í¿¡³ÊÁö¹æ»ç¼±
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secretory component
    ºÐºñ¼ººÐ
  • series elastic component
    Á÷·Äź·Â¼ººÐ(òÁ æê÷¥æ³à÷ÝÂ).
  • slow component
    ¿Ï¼­¼ººÐ(èÐßïà÷ÝÂ).
  • third component
    Á¦»ï¼ººÐ(ð¯ß²à÷ÝÂ).
  • thromboplastin plasma component
    Ç÷¼ÒÆÇ¼º Ç÷À强ºÐ(úìá³÷ùàõúìíìà÷ÝÂ).
  • cellular adhesiveness
    ¼¼Æ÷ºÎÂø¼º
  • cellular aging
    ¼¼Æ÷³ëÈ­(á¬øàÖÕûù)
  • cellular antibody
    ¼¼Æ÷(¼º)Ç×ü(¡­àõù÷ô÷).
  • cellular blue nevus
    ¼¼Æ÷¼º û»ö¸ð¹Ý
  • cellular cast
    ¼¼Æ÷¼º ¿øÁÖ
  • cellular cast
    ¼¼Æ÷¿øÁÖ
  • cellular cementum
    ¼¼Æ÷½Ã¸àÆ®Áú
  • cellular connective tissue
    ¼¼Æ÷¼º°áÇÕÁ¶Á÷
  • cellular deficiency (acallosal cerebrum)
    ¼¼Æ÷°áÇÌ (³úµéº¸°á¿©³ú)
  • cellular detection
    ¼¼Æ÷°ËÃâ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-energy compound
    °í(ÍÔ)¿¡³ÊÁö È­ÇÕ¹°(ûùùêÚª)
  • high-energy ion scattering
    °í(ÍÔ)¿¡³ÊÁö À̿»ê¶õ(ߤկ)
  • high-energy phosphate donor
    °í(ÍÔ)¿¡³ÊÁö ÀÎ»ê°ø¿©ÀÚ(×òß«Íêæ¨í­)
  • high-level promoter
    °íÀ§(ÍÔêÈ)ÇÁ·Î¸ðÅÍ
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • high-mannose glycoproteins
    ´Ù(Òý)¸¸³ë½º ´ç´Ü¹éÁú(ÓØÓ±ÛÜòõ)
  • high-mannose oligosaccharides
    ´Ù(Òý)¸¸³ë½º °ú´çÁú(ÍûÓØòõ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • high-performance liquid chromatography
    °í¼º´É(ÍÔàõÒö) ¾×ü(äûô÷) Å©·Î¸¶Åä±×·¡ÇÇ
  • high-potential iron protein
    °íÀüÀ§(ÍÔï³êÈ) ö´Ü¹éÁú(ôÑÓ±ÛÜòõ)
  • high-pressure liquid chromatography
    °í¾Ð(ÍÔäâ) ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • high-quality proteins
    °í±Þ ´Ü¹éÁú(ÍÔÐäÓ±ÛÜòõ)
  • high-speed sedimentation equilibrium
    "°í¼Ó ħ°­ÆòÇü(ÍÔáÜöØË½øÁû¬)(¹ý,Ûö)"
  • high-temperature protection regulon
    °í¿Âº¸È£(ÍÔè®ÜÁûÞ) ·¹±Ö·Ð
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high risk group
    °íÀ§Çèµµ±º
  • high signal
    °í½ÅÈ£
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high speed
    °í¼ÓÀÇ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɻý°Ë
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • high voltage radiography
    °í¾ÐÃÔ¿µ¼ú
  • high voltage radiography
    °íÀü¾ÐÃÔ¿µ¼ú
  • HRCT [=high resolution comnputed tomography]
    °íÇØ»óÀü»êÈ­´ÜÃþÃÔ¿µ¼ú
  • paramagnetic high susceptibility
    »óÀÚ¼º°íÀÚÈ­À²
  • pseudodiastole in high intensity proton flow
    °í°­µµ¾çÀÚÀ¯µ¿¿¡¼­ À§À̿ϱâ
  • super high field MR scanner
    ÃʰíÀÚÀåMR½ºÄ³³Ê, ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • ultra high field MR scanner
    ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HPLC high-performance liquid chromatography; high-power liquid chromatography; high-pressure liquid chrom...
HT Hashimoto thyroiditis; hearing test; hearing threshold; heart; heart transplantation, heart transpla...
HMWC high-molecular-weight component
ADCC cell Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EIC Extensive intraductal component
FSC Free secretory component
GC Group Specific Component
HC Helper component
ICA Independent Component Analyses
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cellular blue nevus
    ¼¼Æ÷¼º û»ö ¸ð¹Ý
    û»ö ¸ð¹ÝÀÇ Æ¯ÀÌÇÑ º¯ÇüÀ¸·Î¼­ ÀÓ»óÀû ¹× Á¶Á÷ÇÐÀûÀ¸·Î ¾Ç¼º Èæ»öÁ¾À¸·Î ¿ÀÀεDZ⠽±´Ù. À̰ÍÀº µÐºÎ¿Í õ¹Ì°ñ ºÎÀ§¿¡ È£¹ßÇϸç Ä¿´Ù¶õ û»ö ¶Ç´Â Èæ»öÀÇ ´Ü´ÜÇÑ °áÀý·Î ³ªÅ¸³­´Ù.
  • cellular cementum
    ¼¼Æ÷¼º ¹é¾ÇÁú
    Ä¡¾ÆÀÇ Ä¡±Ù¸éÀ» µ¤°í ÀÖ´Â ¼®È¸È­µÈ ¹°ÁúÀÇ ºÎºÐ. °ñ°ú ºñ½ÁÇÏ¸ç ¹é¾Ç ¼¼Æ÷°¡ ¼Ò¿Í³»¿¡¼­ ¹¯Çô ÀÖ´Ù. ¶ÇÇÑ, ¹é¾ÇÁúÀÇ ¼¼°üÀ» µû¶ó ¿øÇüÁú µ¹±â°¡ »¸¾î ÀÖ°í ÀÌ´Â ÀÎÁ¢ÇÑ ¼Ò¿ÍÀÇ ¼¼°ü°ú ¹®ÇÕÇÑ´Ù. ¼Ò¿Í´Â ÃþÆÇÇüÀ¸·Î Á¤·ÄÇÏ¿© ¼®È¸Áú¿¡ »êÀçÇØ ÀÖ´Ù. ¼¼Æ÷¼º ¹é¾ÇÁúÀº ÁÖ·Î Ä¡±ÙÀÇ Ä¡±Ù´Ü ºÎºÐ¿¡ ±¹¼ÒÈ­µÇ¾î Àִµ¥ ¹«¼¼Æ÷¼º ¹é¾ÇÁú À§¿¡ Ä§ÂøµÉ ¼öµµ ÀÖ°í, ¹é¾ÇÁú Èí¼ö ºÎÀ§¿¡¼­ Ä¡À¯ ÀÛ¿ëÀ» ÇÏÁö ¸øÇÒ ¼öµµ ÀÖ´Ù.
  • cellular connective tissue
    ¼¼Æ÷¼º °áÇÕ Á¶Á÷
    ¼¼Æ÷·Î »çÀ̰¡ ¿¬°áµÇ¾î ÀÖ´Â Á¶Á÷.
  • cellular deficiency
    ¼¼Æ÷ °áÇÌ
    ¼¼Æ÷°¡ À¯ÀüÀû ȤÀº ÀÚ°¡¸é¿ªÀû ¿äÀÎÀ¸·Î ÀÎÇØ¼­ °áÇÌµÈ °Í.
  • cellular detection
    ¼¼Æ÷ °ËÃâ
    ¼¼Æ÷ÀÇ Á¸À縦 °ËÃâÇÏ´Â °Í.
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
    ¼¼Æ÷¿¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯È­ÇÑ »óÅÂ.
  • cellular infiltration
    ¼¼Æ÷ ħÀ±
    ¼¼Æ÷°¡ ħÀ±¿¡ ÀÇÇÏ¿© Ä§ÂøµÈ °Í.
  • cellular invagination
    ¼¼Æ÷ ÇÔÀÔ
    ¼¼Æ÷ÀÇ ¾î¶² ºÎºÐÀÌ ´Ù¸¥ ºÎºÐ³»¿¡ ÇÔÀÔÇÏ´Â °Í.
  • cellular layer
    ¼¼Æ÷ Ãþ
    ¼¼Æ÷°¡ °ÅÀÇ ÀÏÁ¤ÇÑ µÎ²²ÀÇ, ȬÀ̺Ҹð¾çÀÇ Á¶Á÷ ±¸Á¶¸¦ °¡Áö´Â °Í.
  • cellular membrane
    ¼¼Æ÷¼º ¸·
    ¼¼Æ÷ÀÇ Ç¥¸éÀ» µ¤°Å³ª °øµ¿ÀÇ ³»¸éÀ» µ¤´Â, ¶Ç´Â °ø°£À̳ª ±â°üÀ» ³ª´©´Â ¾ãÀº ÃþÀÇ Á¶Á÷.
  • cellular oncogene
    ¼¼Æ÷ ¾Ï À¯ÀüÀÚ
    ¼¼Æ÷ÀÇ ¿øÀο¡ ÀÇÇØ¼­ Á¾¾çÇü¼ºÀ» ÀÏÀ¸Å°´Â À¯ÀüÀÚ.
  • cellular pole
    ¼¼Æ÷ ±Ø
    ¼¼Æ÷ÀÇ ÃàÀÇ ¾î´À ÇÑÂÊ ³¡ºÎºÐ. ¼¼Æ÷ÀÇ »ó¹ÝµÈ ºÐ¸®ÇÐÀû ¼ºÁúÀ» °¡ Áø µÎ Á¡ ÁßÀÇ Çϳª.
  • cellular proliferative layer
    ¼¼Æ÷¼º Áõ½ÄÃþ
    ¼¼Æ÷ÀÇ µ¿ÀÏÇüÅÂÀÇ Àç»ý»ê ¶Ç´Â Áõ½ÄÃþ.
  • cellular radiobiology
    ¼¼Æ÷ ¹æ»ç¼± »ý¹°ÇÐ
    ±¤¼±, Àڿܼ±, Àü¸®¹æ»ç¼±ÀÇ Á¶Á÷, ¼¼Æ÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¿¬±¸´ë»óÀ¸·Î ÇÑ °úÇÐÀÇ ÇÑ ºÐ¾ß.
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
secretory component of IgA <immunology, protein> A polypeptide chain of about 60 kD that aids secretion of the IgA, a portion of the IgA receptor on the plasmalemma of the inner side of the epithelial cells lining the gut, which is proteolysed when the IgA receptor complex has travelled through the cell after receptor mediated endocytosis at the inner face, to the outer (luminal) face.
(18 Nov 1997)
serum amyloid P component Precursor of amyloid component P, found in basement membrane. Member of the pentraxin family.
See: serum amyloid.
(18 Nov 1997)
two-component plasma <radiobiology> Refers to a plasma containing a cool thermal component and a population of high energy particles (such as from neutral beam injection) which are in the process of thermalising (slowing down).
(09 Oct 1997)
fast component <molecular biology> A segment of eukaryotic DNA consisting of highly-repeated nucleotide sequences which, when the entire duplex DNA molecule is denatured (the double-stranded helix comes apart and becomes single strands) and then allowed to renature (the complementary single strands come together to form a helix), will be the first segment to renature.
(09 Oct 1997)
acute cellular rejection Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage.
See: primary rejection.
Synonym: acute rejection.
(05 Mar 2000)
cellular 1. Relating to, derived from, or composed of cells.
2. Having numerous compartments or interstices.
Origin: L. Cellula, dim. Of cella, storeroom
(05 Mar 2000)
cellular biology <study> The study of cells. Implies the use of light or electron microscopic methods for the study of morphology.
(18 Nov 1997)
cellular biophysics Biophysics concerned with cellular processes.
(05 Mar 2000)
cellular blue nevus A large, acquired blue nevus in which melanocytes are often clear and large, alternating with pigmented spindle cells and which may expand deeply into the subcutis; malignant change is very rare.
(05 Mar 2000)
cellular cartilage An embryonic or immature stage of cartilage in which it consists chiefly of cells with very little matrix.
Synonym: parenchymatous cartilage.
(05 Mar 2000)
cellular embolism Embolism due to a mass of cells transported from disintegrating tissue.
(05 Mar 2000)
cellular engineering <technique> The use of techniques for constructing replacement or additional or experimental parts of cells and tissues for both fundamental investigation and as prosthetic devices. Often involves the interfacing of cells and nonliving structures.
(26 Mar 1998)
cellular immune theory A concept, put forth by Elie Metchnikoff, that cells, not antibodies, were responsible for the immune response of an organism.
(05 Mar 2000)
cellular immunity <cell biology, immunology> Immune response that involves enhanced activity by phagocytic cells and does not imply lymphocyte involvement. Since the term is easily confused with cell-mediated immunity its use in this sense should be avoided.
(26 Mar 1998)
cellular immunity deficiency syndrome <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind.
See: immunodeficiency.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-toned
    °¡¶ôÀÌ ³ôÀº
  • High Dutch
    =High German
  • High Street
    Å«(¹øÈ­ÇÑ) °Å¸®
  • Lord High Chancellor
    ´ë¹ý°ü
  • Middle High German
    Áß¼¼(Áß±â) °íÁö µ¶ÀϾî(12-15¼¼±â)
  • Old High German
    =GERMAN
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • extremely high frequency
    (Åë½Å)ÃʰíÁÖÆÄ
  • high
    ³ôÀº;...ÀÇ ³ôÀÌÀÇ;³ôÀº °÷(À¸·ÎºÎÅÍ)ÀÇ;°íÁöÀÇ;°í±Í(°í»ó,¼þ°í)ÇÑ;°í¿øÀÇ;°íÀ§ÀÇ;°í±ÞÀÇ;°ªºñ½Ñ;°Ý·ÄÇÑ;±ØµµÀÇ;°ú°ÝÇÑ;£Àº
  • high
    (¿¬°áÇü)(~³ôÀÌÀÇ)ÀÇ ¶æ
  • high Church
    °í±³È¸ÆÄ(¿µ±¹ ±³È¸ÆÄ Áß,±³È¸ÀÇ ±³ÀÇ ¹× ÀǽÄÀ» Á¸ÁßÇÏ´Â ÇÑÆÄ)
  • high Churchman
    °í±³È¸ÆÄ ½Åµµ
  • high Court
    °íµî¹ý¿ø
  • high German
    GERMAN
  • high Mass
    (Ä«Å縯) Àå¾öÇÑ ¹Ì»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á